SynthesisFrontiers in psychiatry2022
The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis.
Synthesis in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Neural correlates of response inhibition following cognitive behavioral therapy in obsessive-compulsive disorder: a randomized controlled EEG study.BMC psychology · 2026Trial
- Case Report: A Multimodal Treatment Approach Combining Multi-Target rTMS with a Modified, Largely Self-Administered, Clinician-Supervised Exposure and Response Prevention Protocol Using a Verbal Termination Cue in Two Patients with Severe Obsessive-Compulsive Disorder.Journal of clinical medicine · 2026Article
- Article
- Neurofeedback interventions for obsessive-compulsive and related disorders: Current evidence and future directions.Journal of psychiatric research · 2026Review
- Designing and Evaluating Digital Mental Health Interventions: Scoping Review.JMIR mental health · 2026Article
- Review
- Beating OCD and Learning Digitally (BOLD): an open trial of a therapist-supported, self-guided exposure and response prevention app for adults with OCD.Cognitive behaviour therapy · 2026Article
- Predictive validity of the Obsessive-Compulsive Inventory-4 and Florida Obsessive-Compulsive Inventory-II severity scale.Journal of psychiatric research · 2026Article
- Retrospective Analysis of Compulsive-like Long-Standing Unacceptable Urination in Cats.Veterinary sciences · 2026Article
- Clinical practice guidelines for obsessive-compulsive disorder: 2025 update.Indian journal of psychiatry · 2026Article
- Enhancing readiness for exposure and response prevention in obsessive compulsive disorder: ketogenic metabolic therapy as a candidate readiness adjunct.Frontiers in psychology · 2026Review
- Subtypes of Severe OCD and Treatment Outcome: A Latent Profile Analysis of the Yale-Brown Obsessive-Compulsive Severity Scale.Cognitive therapy and research · 2025Article
- Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.Current gene therapy · 2025Review
- The Advantages of Combining Therapies in Treating Psychiatric Patients.Brain sciences · 2024Article
- Long-term effectiveness and cost-effectiveness of guided internet-based cognitive behavioral therapy for obsessive-compulsive disorder: 24-month follow-up.Internet interventions · 2024Article
- Variations in obsessive compulsive disorder symptomatology across cultural dimensions.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the effectiveness of exposure and response prevention (ERP) combined with medication on obsessive-compulsive disorder (OCD). Methods: PubMed, Web of Science, EBSCO, Cochrane, Embase, and Science Direct databases were searched to include randomized controlled trials of ERP combined with medication for OCD that met the criteria. The Yale Brown Obsessive Compulsive Scale was used as the primary outcome indicator, and Depression scales were used as secondary outcome indicators. An evaluation of bias risk was conducted to identify possible sources of bias based on methodological and clinical factors. Review Manager 5.3 and Stata 16.0 software was used to perform meta-analysis of the extracted data. Results: A total of 21 studies with 1113 patients were included. Meta-analysis showed that ERP combined with medication therapy was significantly better than medication therapy alone including selective serotonin reuptake inhibitors, clomipramine and risperidone (MD = -6.60, 95% CI: -8.35 to -4.84, Conclusion: Patients with OCD have significant improvement in symptoms of obsessive-compulsive disorder and depression when ERP is combined with medication, however, not enough to prove that DCS can enhance ERP effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.